Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam continuous infusion for procedural or intraoperative sedation
ACTRN12623000133639Phase 4Not yet recruiting
- Sponsor
- Antonia Kustura, MD
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in None, sponsored by Antonia Kustura, MD. Primary endpoints: Necessary continuous dose range of remimazolam and Sedation depth and recovery. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ACTRN12623000133639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000133639.